Alterity Therapeutics Ltd
Company Profile
Business description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Contact
350 Collins Street
Suite 4, Level 14
MelbourneVIC3000
AUST: +61 393494906
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
9
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
stocks
ASX energy giant undervalued despite commissioning challenges
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,199.70 | 30.70 | 0.33% |
| CAC 40 | 8,408.27 | 50.51 | -0.60% |
| DAX 40 | 25,460.48 | 3.53 | -0.01% |
| Dow JONES (US) | 51,581.54 | 1,165.78 | -2.21% |
| FTSE 100 | 10,908.41 | 37.39 | 0.34% |
| HKSE | 25,807.92 | 497.07 | 1.96% |
| NASDAQ | 24,466.90 | 410.01 | -1.65% |
| Nikkei 225 | 61,434.19 | 930.73 | -1.49% |
| NZX 50 Index | 13,976.67 | 114.74 | 0.83% |
| S&P 500 | 7,322.89 | 105.89 | -1.43% |
| S&P/ASX 200 | 9,038.60 | 35.10 | 0.39% |
| SSE Composite Index | 3,828.47 | 15.15 | 0.40% |